Fri, Aug 29, 2014, 1:56 AM EDT - U.S. Markets open in 7 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 17 posts  |  Last Activity: Aug 7, 2014 2:25 PM Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Good buying opportunity!

    by resource405 Aug 6, 2014 9:21 AM
    kadaicher1 kadaicher1 Aug 7, 2014 2:25 PM Flag

    You could be right, but they would need to show some signal in the extension trial. Maybe an aggressive Parkinson's program could do it.

    Sentiment: Strong Buy

  • Reply to

    Tau Joins APP in the Ironworks

    by interestingtome Aug 4, 2014 2:05 PM
    kadaicher1 kadaicher1 Aug 7, 2014 2:21 PM Flag

    Finkelstein has his own synaptic lab at the Florey. Ashley Bush is the head of the oxidization lab, Cherny is his deputy and Adlard is a senior research fellow at the same lab. Masters is division head.
    Combined with strong links to the labs at Harvard, there is some powerful research muscle driving this small company.
    Nice posts interestingtome, thanks.

    Sentiment: Strong Buy

  • Reply to

    Tau Joins APP in the Ironworks

    by interestingtome Aug 4, 2014 2:05 PM
    kadaicher1 kadaicher1 Aug 5, 2014 11:56 PM Flag

    Bush has backed his statement with some elegant research, whereas your statement is truly stupid, implying everything is already known about these processes.
    (Now, Bush and colleagues have discovered that samples of human brain tissue affected by Parkinson's disease contain lower levels of soluble tau but elevated levels of iron. This lack of tau protein, they suggest, could increase iron levels in the brain and cause neurodegeneration.

    The team tested what happened to transgenic mice without the tau gene. They found that at 12 months old the mice were cognitively impaired in a maze test and there was severe degeneration in the cortex and substantia nigra regions of the brain - the areas typically affected in Alzheimer's and Parkinson's, respectively. What's more, they observed that iron accumulated in these regions.

    When the team put 6 and half month old tau knockout (KO) mice on a diet containing the drug clioquinol, a non-toxic iron chelator, they found it halted iron accumulation in the affected tissue and completely rescued cognitive and pathological degeneration, providing evidence that iron causes neurodegeneration.

    'Treating a tau KO mouse with an iron chelator was not an experiment you would have predicted to be obvious from the existing literature,' says Bush. 'We were quite stunned by how profoundly clioquinol rescued the tau KO mice.' A further experiment revealed that a lack of tau impairs the trafficking of a protein involved in neuronal iron export.)

    Sentiment: Strong Buy

  • Reply to

    So what happens if...

    by daniel.kiely Aug 3, 2014 11:12 AM
    kadaicher1 kadaicher1 Aug 3, 2014 12:07 PM Flag

    That is the point, if they can win approval for HD and show some more in the IMAGINE extension, it could also be considered off label for AD patients.

    Sentiment: Strong Buy

  • Reply to

    So what happens if...

    by daniel.kiely Aug 3, 2014 11:12 AM
    kadaicher1 kadaicher1 Aug 3, 2014 12:02 PM Flag

    They have plenty to fund a HD trial and I think that is where they should be going. The Parkinson's drug should be in a position to add value before too long and may cover any dilution.
    It is too soon to speculate on AD trials before the end of the IMAGINE extension trial in my opinion. In such a very early stage of the disease the extra year may help PBT2 demonstrate gains and give us a further demonstration of slowing atrophy as placebo cross to drug arm.,

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 5, 2014 11:58 PM Flag

    I also think Prana are on the right track. They need to do more than slowing the atrophy. Prana have demonstrated they can affect the process and I agree now need to escalate the dose.
    There is a normal brain atrophy rate in the elderly and I would like to see them go after that as well. That may be where AD can be eliminated.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 3, 2014 4:28 PM Flag

    Here, but unable to attend.Everything changes so fast. When the first stage of IMAGINE ended, and all they saw to that stage was a reduction in brain atrophy, we didn't know brain atrophy was the most reliable marker of degeneration. Now we know. Many were saying the drug is right and the dose too low. Now we have crossovers in the extension trial to confirm drug related reduction in atrophy rate. Question is will they go after AD again with a higher dose, or easier targets like early HD and PD with 434, or even a combination. I hope their talks will be available on line.

    Sentiment: Strong Buy

  • Reply to

    PRAN HAS HIGHEST CASH POSITION EVER OF 41 MILLION

    by rkf302 Jun 30, 2014 2:20 PM
    kadaicher1 kadaicher1 Jul 3, 2014 1:13 AM Flag

    Prana can do a lot with 10 million. 41 million has to be very comfortable for them. When the Phase3 HD is announced there should be a spike. The new Parkinsons drug should cause some interest. The remaining AD results will be very interesting and will shed more light on future direction there. I would like to see a major effort into Parkinson's and HD before the final AD results.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 22, 2014 2:35 PM Flag

    I think it was worth a shot. From the previous trials they saw a natural decrease in AB42, now a reduction in brain atrophy in two trials. It did reduce plaque. They built more safety profile, and an Alzheimer's trial is still running. That PBT2 did not reduce AB42 in plasma after clearly demonstrating PBT2 reduces AD42 in the brain(CSF) is also important info.

    Sentiment: Strong Buy

  • Reply to

    So, who is lurking?

    by inversor86 Jun 18, 2014 4:17 PM
    kadaicher1 kadaicher1 Jun 22, 2014 2:24 PM Flag

    Still here with half of my stock and still in 6 digits. The tiny IMAGINE trial managed to somehow hurt confidence in the Reach2HD results. The co has stated they will spend some time on the results, but I cannot see how anything has changed regarding time to market for HD.
    Still a reduction in brain atrophy to look at in the IMAGINE extension placebo crossovers and maybe some longer term effects.
    I also happen to think there will soon be a major effort into Parkinson's.
    Don't have much time to post these days. I will finish a project I am on shortly and that will change. Good luck to fellow longs.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 12, 2014 12:42 AM Flag

    HD has always been the route to market and not much has changed there. Stay tuned for a short trial for approval in HD. NOTHING regarding that route to market has changed since the 500m market cap. Copper you have very selective vision. HD looks strong in early stage HD and the PD drug about to enter the clinic has spectacular pre clinical results. The AD trial is still ongoing.

    Sentiment: Strong Buy

  • Things are looking good for further development. Anyone who says different has not done their homework.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 11, 2014 12:14 PM Flag

    Thick as two short planks. A company with a blockbuster drug has a market cap closer to 10 billion. This company does have very high potential for a blockbuster.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 8, 2014 12:59 AM Flag

    Not much doubt their atrophy will slow. That was seen in a very small HD sample, then the AD trial, and probably now in the extension trial. I think that will be fairly big news, because it will prove disease modification in that biomarker. We already know if decreases the toxic AB42 in the brain only. The IMAGINE trial did not pick up a corresponding AB42 decrease in the blood. With a stellar safety profile, I think they are ready to raise the dose.

    Sentiment: Strong Buy

  • which has already demonstrated a slowing of brain atrophy. That is what you may expect given the research results showing restoration of neurons, synapses etc. Alzheimer's is a very complicated condition and PBT2, at this or higher doses may be a big part of the answer. Let's see what happens with 24 months treatment. The AD effort is a long way from over.
    That the small IMAGINE trial did not show any cognition changes over a year in very early patients where there is almost no deterioration is not so surprising. 24 months may show a different result.
    Meanwhile just waiting on word of the HD phase3 pivotal for approval.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 1, 2014 2:22 AM Flag

    I think it tells us Prana is going to have to go for a higher dose. I know it is a mouse study and a human study, but everything so far indicates a higher dose. It is probably safer to take care of the HD trial before they do that. With the 10 fold dose, the reduction in atrophy turned into a size increase. Lindquist identified where it gets tricky. In her model she demonstrated that MPACs were most efficious just before reaching toxicity. I think Prana have a little more work to do on AD while they are doing the HD phase3.
    Thanks for posting that Pivalde.

    Sentiment: Strong Buy

  • Reply to

    When will the dilution hit?

    by cramerblows_a_s_s May 29, 2014 11:19 AM
    kadaicher1 kadaicher1 May 30, 2014 2:39 AM Flag

    That is an old article which was true when it was written. It is no longer accurate. They have enough to progress the HD trial for approval, they have one of the worlds top HD investigators now on the board. After another 12 months there could be some raising. It depends how hard they want to proceed with the Parkinson's drug. Anyway, at that point the price will be higher with the HD trial on and maybe the IMAGINE extension trial will kick out some more useful data.
    Now would probably be the time to plan to increase dosage with IMAGINE AD patients who wish to continue.

    Sentiment: Strong Buy

PRAN
2.17+0.08(+3.58%)Aug 28 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.